ASCO 2026

Oncology

ASCO 2026: Are radiopharmaceuticals being systematically und...

The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Oncology

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.

Patients

ASCO 26: Three cancer survivors share lessons for the field

In honour of National Cancer Survivors' Day, we recount three patient testimonies and calls to action from ASCO Voices at ASCO 2026.

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Oncology

Female cancer survivor and her grown daughter

Cancer patients don’t care where the breakthrough happened. ...

National Cancer Survivors’ Day highlighted decades of progress against cancer, but oncology faces a new challenge.

ASCO 2026: Are radiopharmaceuticals being systematically und...

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

ASCO 26: Three cancer survivors share lessons for the field

ASCO 2026: Chinese firms take a front seat in oncology, with...

Cancer patients don’t care where the breakthrough happened. ...

AstraZeneca’s volrustomig hits Phase 3 setback in lung cance...

Discover a new era of healthcare panel engagement: Grounded ...

ASCO 2026

Editor's Picks